← All trials
NCT05034874
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2022
- Primary completion
- Oct 31, 2023
- Completion date
- Dec 20, 2023
- First posted
- Sep 5, 2021
- Last posted
- Oct 25, 2021
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- InterveXion Therapeutics, LLCLead sponsor
- National Institute on Drug Abuse (NIDA)Collaborator
- InterveXion Therapeutics, LLCStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.